文献速递慢性肾脏病

慢性肾脏病不同阶段肠道菌群生成蛋白结合尿毒症毒素及相关代谢物未改变

Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
PubMed 文献 · Kidney Int · 2020-02-17

该研究纳入14名对照和141例CKD患者,检测粪便、血浆和尿液代谢物浓度,并进行粪便体外厌氧培养。随CKD进展,血浆蛋白结合尿毒症毒素水平升高,但粪便和尿液中毒素及前体水平不变,体外生成速率也无差异。提示血浆毒素升高主要因肾功能受损导致潴留,而非肠道细菌生成增加。

要点

  • CKD进展中血浆蛋白结合尿毒症毒素升高,但粪便和尿液水平不变。
  • 肠道细菌体外生成p-甲酚、吲哚和吲哚-3-乙酸速率无差异。
  • 血浆毒素升高主要归因于肾功能受损导致潴留,而非肠道生成增加。

核心结论

  • CKD不同阶段血浆蛋白结合尿毒症毒素水平的差异不能由肠道细菌生成速率差异解释。
  • 肾功能受损导致潴留是血浆蛋白结合尿毒症毒素升高的主要因素。

研究设计与样本

  • 研究纳入14名对照个体和141例CKD患者,收集粪便、血浆和尿液。
  • 采用超高效液相色谱定量溶质,并进行粪便体外厌氧培养评估细菌生成速率。

主要发现

  • 随CKD进展,血浆蛋白结合尿毒症毒素水平升高,而粪便和尿液中这些毒素及前体水平保持不变。
  • 粪便样本厌氧培养显示p-甲酚、吲哚和吲哚-3-乙酸的体外生成无差异。

关键数值与推荐

  • 随CKD进展,分数清除率下降,且肾小管清除似乎比肾小球滤过率受影响更明显。
  • 血浆蛋白结合尿毒症毒素水平升高时,进入肠腔的净流入量未增加。

临床怎么用

  • 临床降低蛋白结合尿毒症毒素应聚焦于改善肾功能或替代清除,而非仅调控肠道菌群生成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) is characterized by accumulation of protein-bound uremic toxins such as p-cresyl sulfate, p-cresyl glucuronide, indoxyl sulfate and indole-3-acetic acid, which originate in the gut. Intestinal bacteria metabolize aromatic amino acids into p-cresol and indole, (further conjugated in the colon mucosa and liver) and indole-3-acetic acid. Here we measured fecal, plasma and urine metabolite concentrations; the contribution of gut bacterial generation to plasma protein-bound uremic toxins accumulation; and influx into the gut of circulating protein-bound uremic toxins at different stages of CKD. Feces, blood and urine were collected from 14 control individuals and 141 patients with CKD. Solutes were quantified by ultra-high performance liquid chromatography. To assess the rate of bacterial generation of p-cresol, indole and indole-3-acetic acid, fecal samples were cultured ex vivo. With CKD progression, an increase in protein-bound uremic toxins levels was observed in plasma, whereas the levels of these toxins and their precursors remained the same in feces and urine. Anaerobic culture of fecal samples showed no difference in ex vivo p-cresol, indole and indole-3-acetic acid generation. Therefore, differences in plasma protein-bound uremic toxins levels between different CKD stages cannot be explained by differences in bacterial generation rates in the gut, suggesting retention due to impaired kidney function as the main contributor to their increased plasma levels. Thus, as fractional clearance decreased with the progression of CKD, tubular clearance appeared to be more affected than the glomerular filtration rate, and there was no net increase in protein-bound uremic toxins influx into the gut lumen with increased plasma levels.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gryp T, De Paepe K, Vanholder R, et al. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Kidney Int. 2020. PMID: 32317112. doi:10.1016/j.kint.2020.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。